China Medical University Hospital Develops IV Neural Stem Cell-Derived Exosome Spinal Cord Injury Candidate

Key Points

• China Medical University Hospital and its industry partners have developed a targeted stem cell exosome therapy for acute spinal cord injury.
• It’s designed for IV delivery of BDNF mRNA to injured spinal cord tissue, and in rat preclinical models, showed improved motor coordination and reduced inflammation/secondary oxidative damage at the injury site.

China Medical University Hospital (CMUH), Ever Supreme International Biotechnology Co., Ltd., and SHINE OUT BIO TECHNOLOGY CO., LTD., have unveiled a gene-engineered induced pluripotent stem cell (iPSC)-derived neural stem cell exosome therapy for acute spinal cord injury.

The IV exosome therapy delivers lesion-targeted brain-derived neurotrophic factor (BDNF) mRNA and has been reported to improve motor coordination in preclinical models. The findings were published in the Journal of Nanobiotechnology.

Send me the newsletter, I agree to the privacy policy*

Yes

Subscribe

Send me the newsletter, I agree to the privacy policy*

Yes

Subscribe

CMUH said the therapy will hopefully address two common limitations with other stem cell therapies for spinal cord injury:

• The need for intrathecal administration, which carries significant risk (a few years ago, a handful of patients received intrathecal MSCs in Mexico, and came back with meningitis)
• The limited targeting ability of conventional exosomes after systemic delivery

How it works

First off, it should be noted that spinal cord injury is one of medicine’s most difficult areas; most patients face permanent disability and long-term rehabilitation. However, a variety of companies are developing solutions using mesenchymal stem cells (check out our interview with NurExone Biologic on their siRNA-loaded MSCs), neural stem cells, and other therapies.

According to these researchers, cells in the injured spinal cord microenvironment upregulate the integrin αvβ8 molecular marker. So, they engineered exosomes to display a corresponding recognition ligand on their surface, creating the αITG EV (extracellular vesicle) targeting carrier. The exosomes were also loaded with BDNF mRNA, a therapeutic payload associated with neural repair.

In preclinical work, the therapy was reported to produce both immunomodulatory and metabolic effects, including:

• Shifting local microglia from a pro-inflammatory state to a reparative phenotype
• Reducing inflammatory cytokines, including TNF-α and IL-1β
• Enhancing antioxidant protein expression
• Stabilizing mitochondrial dynamics
• Reducing secondary oxidative damage

Development and next steps

In January 2026, Ever Supreme International Biotechnology Co., Ltd. integrated SHINE OUT BIO TECHNOLOGY CO., LTD. through a share-swap transaction to expand its exosome and cell therapy capabilities in central nervous system applications. The companies said this combination brings together CMUH’s clinical experience and the partners’ manufacturing capabilities.

Ming-Chuan Li, Deputy General Manager of SHINE OUT BIO TECHNOLOGY CO., LTD., said Taiwan’s regenerative medicine framework may support future clinical development and regulatory review for therapies targeting severe disability and life-threatening conditions. The group said it plans to continue development within the applicable regulatory pathway and explore future patient access, subject to safety, efficacy, and regulatory requirements.

“Time is the most precious resource for patients with spinal cord injuries,” Li said. “We hope continued development of this platform will expand future treatment options for patients.”

Want to keep up on regenerative medicine? Get the weekly newsletter here.